Pipeline ― State of New Product Development

Central nervous system

MT-5199

Tardive dyskinesia

Product nameDysvalGeneric nameValbenazineMechanism(Indications)Vesicular monoamine transporter type 2 inhibitor(Tardive dyskinesia)Origin/licenseeLicensed from Neurocrine Biosciences (US)

Central nervous system

MT-210

Schizophrenia

Generic nameRoluperidoneMechanism(Indications)5-HT2A/Sigma 2 receptor antagonist(Schizophrenia)Origin/licenseeLicensed to Minerva Neurosciences (US)

Central nervous system

MT-210

Schizophrenia

Generic nameRoluperidoneMechanism(Indications)5-HT2A/Sigma 2 receptor antagonist(Schizophrenia)Origin/licenseeLicensed to Minerva Neurosciences (US)

Central nervous system

ND0612

Parkinson's disease

Generic nameLevodopa/CarbidopaMechanism(Indications)Continuous SC pump(Parkinson's disease)Origin/licenseeIn-house

Central nervous system

MT-0551

Myasthenia gravis

Product nameUpliznaGeneric nameInebilizumabMechanism(Indications)Humanized anti-CD19 monoclonal antibody(Myasthenia gravis)Origin/licenseeLicensed from Amgen (US) and co-developed (Global study ongoing)

Central nervous system

MT-8554

Peripheral neuropathic pain

Generic nameElismetrepMechanism(Indications)TRPM8 antagonist(Peripheral neuropathic pain)Origin/licenseeIn-house

Central nervous system

MT-3921

Spinal cord injury

Generic nameUnasnemabMechanism(Indications)Anti-RGMa antibody(Spinal cord injury)Origin/licenseeCo-discovered with Osaka University (Japan)

Central nervous system

MT-3921

HTLV-1 associated myelopathy

Generic nameUnasnemabMechanism(Indications)Anti-RGMa antibody(HTLV-1 associated myelopathy)Origin/licenseeCo-discovered with Osaka University (Japan)

Immuno-inflammation

MT-7117

Erythropoietic protoporphyria, X-Linked protoporphyria

Generic nameDersimelagonMechanism(Indications)Selective melanocortin 1 receptor agonist(Erythropoietic protoporphyria, X-Linked protoporphyria)Origin/licenseeIn-house

Immuno-inflammation

MT-7117

Systemic sclerosis

Generic nameDersimelagonMechanism(Indications)Selective melanocortin 1 receptor agonist(Systemic sclerosis)Origin/licenseeIn-house

Immuno-inflammation

MT-0551

IgG4-related disease

Product nameUpliznaGeneric nameInebilizumabMechanism(Indications)Humanized anti-CD19 monoclonal antibody(IgG4-related disease)Origin/licenseeLicensed from Amgen (US) and co-developed (Global study ongoing)

Immuno-inflammation

MT-0551

Systemic sclerosis

Product nameUpliznaGeneric nameInebilizumabMechanism(Indications)Humanized anti-CD19 monoclonal antibody(Systemic sclerosis)Origin/licenseeLicensed from Amgen (US)

Immuno-inflammation

MT-2990

Endometriosis

Mechanism(Indications)Fully human anti-interleukin-33 (IL-33) monoclonal antibody(Endometriosis)Origin/licenseeIn-house

Oncology

MT-2111

Relapsed/Refractory Diffuse Large B-cell Lymphoma

Generic nameLoncastuximab tesirineMechanism(Indications)Anti-CD19 antibody drug conjugate(Relapsed/Refractory Diffuse Large B-cell Lymphoma)Origin/licenseeLicensed from ADC Therapeutics (Switzerland)

Oncology

MT-2111

Relapsed/Refractory Diffuse Large B-cell Lymphoma (with rituximab)

Generic nameLoncastuximab tesirineMechanism(Indications)Anti-CD19 antibody drug conjugate(Relapsed/Refractory Diffuse Large B-cell Lymphoma (with rituximab))Origin/licenseeLicensed from ADC Therapeutics (Switzerland) and co-developed (Global study ongoing)

Others

MT-4580

Secondary Hyperparathyroidism

Product nameOrkediaGeneric nameEvocalcetMechanism(Indications)Ca sensing receptor agonist(Secondary Hyperparathyroidism)Origin/licenseeLicensed to Kyowa Kirin (Japan)

Others

MT-2765

Hypertension

Mechanism(Indications)Renin inhibitor(Hypertension)Origin/licenseeLicensed to Shanghai Pharmaceuticals (China)